ROCKVILLE, Md., May 8, 2023
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it
will participate in the following upcoming investor
conferences:
BofA Securities 2023 Health Care
Conference
Fireside Chat Date: Wednesday, May 10, 2023
Fireside Chat Time: 5:00 p.m.
PT
Location: Las Vegas, NV
RBC 2023 Global Healthcare Conference
Fireside Chat
Date: Tuesday, May 16, 2023
Fireside Chat Time: 3:35 p.m.
ET
Location: New York,
NY
UBS Spring Biotech Conference
Date:
Tuesday, May 23, 2023
Location: New York,
NY
A live webcast of the fireside chats can be accessed in the
Investors section of REGENXBIO's website at www.regenxbio.com. An
archived replay of the webcast will be available for approximately
30 days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology
Platform Licensees are applying the NAV Technology Platform in the
development of a broad pipeline of candidates, including late-stage
and commercial programs, in multiple therapeutic areas. REGENXBIO
is committed to a "5x'25" strategy to progress five AAV
Therapeutics from our internal pipeline and licensed programs into
pivotal-stage or commercial products by 2025.
Contacts:
Dana
Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301817946.html
SOURCE REGENXBIO Inc.